Endocrine Abstracts

In overt or subclinical ACTH-independant Cushing’s syndrome (CS), aberrant adrenal receptors may control cortisol secretion.We systematically studied the 20 patients with adrenal incidentaloma screened in our department for illegitimate adrenal receptors between 2000 and 2006. We investigated plasma cortisol level during successive stimulation tests performed while dexamethasone was given orally every 8 h (upright posture, meal, hypothalamic hormone...

Introduction: The syndrome of reduced sensitivity to thyroid hormone (SRSTH) due to mutations of thyroid hormone receptor β (TRB) consists of an inappropriate secretion of TSH with elevated levels of thyroid hormones. Cardiovascular manifestations are often the ones that affect patients. Our aim was to evaluate the cardiac and vascular characteristics of patients with SRSTH due to TRB mutations.Materials and methods: We analysed cl...

IntroductionProgressive and radioiodine-refractory thyroid cancer has poor outcomes and limited therapeutic options (i.e tyrosine kinase inhibitors) due to the transient efficacy of treatment and toxic effects. Therefore, combinatorial treatment with new therapeutic approaches are needed. Many studies link G Protein-Coupled Receptors (GPCRs) to cancer. The aim of this study is to present the first specific atlas of GPCRs expression in progressive and ref...

Background: Hyperphagia leading to craniopharyngioma-related obesity (CRO) is a common and serious sequel of treatments of craniopharyngiomas. The few therapeutic approaches that have been tested until now for the control of eating behaviour and weight have poor efficacy. Glucagon-like peptide-1 (GLP-1) analogues might be an option. Methods: This multicentre, randomised, double-blind superiority trial was conducted in France. Adults with CRO (BMI > 3...

Background: Radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) patients with distant metastases show poor survival rates. However, patients’ outcome can be very heterogeneous, with cases spanning from microscopic slowly growing metastases to symptomatic, rapidly progressive disease. The aim of this study was to assess the overall survival (OS) of RAI-R DTC patients with distant metastases and to identify the prognostic factors associated with OS.<p class...

Introduction: Vandetanib was the first tyrosine kinase inhibitor approved for the first line systemic treatment of progressive metastatic or locally advanced medullary thyroid carcinomas (MTC). Previous studies reported median duration of treatment (DOT) around 20 months with a subset of patients presenting long-term responses. Little is known on the impact of RET mutation status on the response duration.Objectives: To evaluate the proportion and compare...